Pfizer’s Talzenna-Xtandi Combo Shows Significant Survival Benefit in Advanced Prostate Cancer
The combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improved overall survival in patients with mCRPC, regardless of HRR gene mutation status12.
In patients unselected for HRR mutations, the combination therapy extended median overall survival to 45.8 months compared to 37.0 months with Xtandi alone, representing a 20% reduction in the risk of death45.
For patients with HRR-mutated mCRPC, the combination therapy showed a median overall survival of 45.1 months versus 31.1 months with Xtandi alone, equating to a 38% reduction in the risk of death14.
The TALAPRO-2 trial involved 1,035 patients with mCRPC across 184 international sites1.
Pfizer is seeking to update Talzenna's label with these results, potentially expanding its use to a broader patient population23.
This combination is the first and only PARP inhibitor plus androgen receptor pathway inhibitor (ARPI) to demonstrate a statistically significant overall survival benefit in mCRPC patients7.
The safety profile of the combination therapy remained consistent with the known profiles of each individual drug10.
Sources:
1. https://www.clinicaltrialsarena.com/news/pfizers-talzenna-gains-14-months-os-lead-over-mcrpc-soc/
2. https://www.appliedclinicaltrialsonline.com/view/talzenna-xtandi-metastatic-castration-resistant-prostate-cancer
3. https://www.ajmc.com/view/talapro-2-overall-survival-data-suggest-new-standard-of-care-in-mcrpc-regardless-of-genomic-status
4. https://www.benzinga.com/25/02/43737281/pfizers-talzennaxtandi-combo-improves-survival-outcomes-in-metastatic-castration-resistant-prostate-cancer
5. https://www.cancernetwork.com/view/talazoparib-and-enzalutamide-improve-outcomes-in-advanced-prostate-cancer
7. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-talzennar-combination-xtandir-prolongs-overall
10. https://www.clinicaltrialvanguard.com/news/pfizer-talzenna-xtandi-improve-survival-in-mcrpc/